According to Zacks, “AEterna Zentaris Inc. is a biopharmaceutical company focused on endocrine therapy and oncology. Its lead endocrinology program is a Phase 3 trial in benign prostatic hyperplasia (BPH) with cetrorelix, an LHRH antagonist already marketed for in vitro fertilization under the brand name Cetrotide. The lead oncology program is a Phase 2 trial in endometrial and ovarian cancer with AEZS-108, a targeted cytotoxic peptide conjugate. Other lead compounds include ozarelix for BPH and prostate cancer as well as perifosine for multiple cancers. “
Other research analysts have also recently issued research reports about the stock. Canaccord Genuity restated a buy rating and issued a $9.00 target price on shares of Aeterna Zentaris in a report on Tuesday, August 23rd. Maxim Group restated a buy rating and issued a $11.00 target price on shares of Aeterna Zentaris in a report on Saturday, August 13th. Finally, HC Wainwright reiterated a buy rating on shares of Aeterna Zentaris in a research note on Thursday, August 11th.
Shares of Aeterna Zentaris (NASDAQ:AEZS) opened at 3.74 on Tuesday. The firm’s market cap is $37.17 million. Aeterna Zentaris has a 12 month low of $2.60 and a 12 month high of $15.70. The stock has a 50 day moving average of $3.52 and a 200 day moving average of $3.55.
Aeterna Zentaris (NASDAQ:AEZS) last issued its earnings results on Tuesday, August 9th. The biopharmaceutical company reported ($0.71) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.82) by $0.11. Aeterna Zentaris had a negative net margin of 5,871.45% and a negative return on equity of 241.78%. On average, equities research analysts expect that Aeterna Zentaris will post ($2.61) EPS for the current fiscal year.
An institutional investor recently raised its position in Aeterna Zentaris stock. Renaissance Technologies LLC raised its position in Aeterna Zentaris Inc. (NASDAQ:AEZS) by 5.9% during the first quarter, according to its most recent disclosure with the SEC. The institutional investor owned 516,833 shares of the biopharmaceutical company’s stock after buying an additional 29,000 shares during the period. Renaissance Technologies LLC owned approximately 8.17% of Aeterna Zentaris worth $1,716,000 at the end of the most recent quarter. 8.33% of the stock is currently owned by hedge funds and other institutional investors.
Aeterna Zentaris Company Profile
Aeterna Zentaris Inc is a specialty biopharmaceutical company engaged in developing and commercializing treatments in oncology, endocrinology and women’s health. The Company operates through the biopharmaceutical segment. The Company is engaged in drug development activities and in the promotion of products for others.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Aeterna Zentaris Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aeterna Zentaris Inc. and related companies with MarketBeat.com's FREE daily email newsletter.